3 unchanged sentences
(c) Director and Officer Trading Plans and Arrangements
−Removed: On August 30, 2024 , Frank McCormick , a member of our Board of Directors , adopted a trading plan on behalf of the Francis P.
−Removed: McCormick Revocable Trust U/A DTD 1/27/2017, of which Dr.
−Removed: McCormick is a trustee, for the sale of a maximum of 300,000 shares of our common stock (the “Trading Plan”).
−Removed: The Trading Plan is intended to satisfy the affirmative defense conditions of the Securities and Exchange Act Rule 10b5-1(c) and is expected to remain in effect until the earlier of (1) November 26, 2025 and (2) the date on which an aggregate of 300,000 shares of our common stock have been sold under such plan.
+Added: On March 31, 2025 , Thomas Trimarchi , our President and Chief Financial Officer , adopted a trading plan (the “Trimarchi Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c).
+Added: The Trimarchi Trading Plan provides for the potential sale of a maximum of (i) 47,887 shares of our common stock held by Dr.
+Added: Trimarchi and (ii) 100% of net vested shares of our common stock to be issued to Dr.
+Added: Trimarchi upon vesting of his restricted stock units (“RSUs”) on
+Added: May 16, 2025.
+Added: On the date when the Trimarchi Trading Plan was adopted, Dr.
+Added: Trimarchi held no such net vested shares.
+Added: Trimarchi’s net vested share amount will change as additional RSUs vest on the applicable vesting date.
+Added: The aggregate number of net vested shares of common stock that will be available for sale by Dr.
+Added: Trimarchi is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of his RSUs on the vesting date.
+Added: Trimarchi is not permitted to transfer, sell or otherwise dispose of any shares under the Trimarchi Trading Plan during the 90-day period following the plan’s adoption.
+Added: The Trimarchi Trading Plan is expected to remain in effect until the earlier of (1) May 29, 2026 and (2) the date on which all transactions under such plan have been completed.
+Added: On March 31, 2025 , Dr.
+Added: Neil Kumar , our Chief Executive Officer and a member of our Board of Directors, adopted a new trading plan (the “Kumar Trading Plan”) intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) on behalf of himself and Kumar Haldea Revocable Trust and Kumar Haldea Family Irrevocable Trust, of which Dr.
+Added: Kumar is a co-trustee.
+Added: The Kumar Trading Plan provides for the potential sale of a maximum of (i) 480,000 shares of our common stock held by Kumar Haldea Family Irrevocable Trust, (ii) 480,000 shares of our common stock held by Kumar Haldea Revocable Trust, and (ii) 100% of net vested shares of our common stock to be issued to Dr.
+Added: Kumar upon vesting of his RSUs on August 16, 2025, November 16, 2025, December 10, 2025, February 16, 2026 and May 16, 2026.
+Added: On the date when the Kumar Trading Plan was adopted, Dr.
+Added: Kumar held no such net vested shares.
+Added: Kumar’s net vested share amount will change as additional RSUs vest on each of these vesting dates.
+Added: The aggregate number of net vested shares of common stock that will be available for sale by Dr.
+Added: Kumar is not yet determinable because the shares available will be net of shares to be withheld to satisfy tax obligations in connection with the vesting of his RSUs on each of these vesting dates.
+Added: Kumar is not permitted to transfer, sell or otherwise dispose of any shares under the Kumar Trading Plan during the 90-day period following the plan’s adoption.
+Added: The Kumar Trading Plan is expected to remain in effect until the earlier of (1) June 5, 2026 and (2) the date on which all transactions under such plan have been completed.
Exhibit Title
25 unchanged sentences
September 25, 2023
−Removed: Transaction Agreement, dated as of August 16, 2024, by and among BridgeBio Pharma, Inc., Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown (Aggregator) LP, Patient Square Bravo Aggregator, LP, SC US/E GROWTH FUND X MANAGEMENT, L.P., SC US/E Venture Fund XVIII Management, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Cormorant Private Healthcare Fund IV, LP, Cormorant Private Healthcare Fund V, LP, Cormorant Global Healthcare Master Fund, LP, Aisling V Bridge Splitter LP, Kumar Haldea Revocable Trust and GondolaBio, LLC.
−Removed: August 21, 2024
−Removed: Amended and Restated Limited Liability Company Agreement of GondolaBio, LLC, dated as of August 16, 2024.
−Removed: August 21, 2024
+Added: Indenture, dated as of February 28, 2025, by and between BridgeBio Pharma, Inc.
+Added: Bank Trust Company, National Association, as Trustee.
+Added: February 28, 2025
+Added: Form of Global Note, representing BridgeBio Pharma, Inc.’s 1.75% Convertible Senior Notes due 2031 ( included as Exhibit A to the Indenture filed as Exhibit 4.1)
+Added: February 28, 2025
+Added: Consulting Agreement, dated March 17, 2025, between BridgeBio Pharma, Inc.
+Added: and Brian Stephenson.
+Added: Filed herewith
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
2 unchanged sentences
Filed herewith
+Added: Certification of Principal Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Filed herewith
Certification of Principal Executive Officer Pursuant to 18 U.S.C.
4 unchanged sentences
Filed herewith
+Added: Certification of Principal Accounting Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Filed herewith
Inline XBRL Instance Document
14 unchanged sentences
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
−Removed: ** Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).
# Indicates a management contract or any compensatory plan, contract or arrangement.
2 unchanged sentences
BridgeBio Pharma, Inc.
−Removed: November 12, 2024
+Added: April 29, 2025
/s/ Neil Kumar
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 12, 2024
−Removed: /s/ Brian Stephenson
−Removed: Brian Stephenson, Ph.D., CFA
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer and Principal Accounting Officer)
+Added: April 29, 2025
+Added: /s/ Thomas Trimarchi
+Added: Thomas Trimarchi, Ph.D.
+Added: President and Chief Financial Officer
+Added: (Principal Financial Officer)
+Added: April 29, 2025
+Added: /s/ Maricel M.
+Added: Chief Accounting Officer
+Added: (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.